Increasing number of patients with bleeding disorders to drive the Global Bleeding Disorders Drugs Market in the forecast period, 2022-2026.
According to TechSci Research report, “Global Bleeding Disorders Drugs Market By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others) By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Gender (Male v/s Female), By End User (Hospitals, Hemophilia Treatment Centers, Research Institutes, Others), By Region, Competition Forecast & Opportunities, 2026”, the Global Bleeding Disorders Drugs Market was valued USD14993.45 million in value terms in 2020 and is forecast to grow at a CAGR of 8.44% and reach USD24078.16 million by 2026.
Browse over 151 market data Figures spread through 110 Pages and an in-depth TOC on “Global Bleeding Disorders Drugs Market”
Global Bleeding Disorder Drugs Market is segmented into drug type, disease type, distribution channel, gender, end user, and regional distribution. Based on regional distribution the market is segmented into five regions of the world, Asia-Pacific, North America, South America, MEA, and Europe. North America and Europe are projected to dominate the market in the forecast period, owing to the facts that the treatment is more affordable, and healthcare is more feasible for patients in these regions. Asia-Pacific region is expected to gain more market share in the forecast period because of the growing economies like India and China in the region.
The disease type segment is further segregated into Hemophilia A, Von Willebrand Disease, Hemophilia B, and others. Hemophilia is a X chromosome linked disorder due to which it mainly occurs in males. Hemophilia A disease segment is dominating the market due to its high epidemiology in males across the globe. Whereas, in the forecast period Von Willebrand Disease will be leading the market as it can occur in males as well as females.
The treatment cost and the lack of availability of treatments to combat bleeding disorders in developing nations is the major hurdle in the growth of Global Bleeding Disorders Drugs industry.
The leading companies are investing into research and development of drugs related to bleeding disorders, which will further drive the industry in the forecast period. The drug type segment is fragmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants and others. Recombinant coagulation factor concentrates segment is dominating the market followed by plasma-derived coagulation factor concentrates. In the forecast period, recombinant coagulation factor concentrates, which are DNA engineered concentrates will be dominating the market as the transmission of infection such as HIV and Hepatitis is least with the usage of these drugs. The major drawback using plasma-derived coagulation factor concentrates is that it is extracted from human blood plasma and the risk of infection is high during infusion of these concentrates.
The end user segment has been further fragmented into hospitals, hemophilia treatment centers, research institutes and Others. In the current period, the hospitals segment is dominating the market whereas in the forecast period hemophilia treatment centers segment is going to lead the market to a significant level.
Some of the major competitors in the market are Bayer AG, Grifols S.A., Pfizer Inc., Octapharma AG, Ferring Pharmaceuticals SA, Sanofi SA, Baxter International Inc., F. Hoffmann-La Roche Ltd., Takeda Pharmaceuticals Ltd., Novo Nordisk A/S, Novartis AG, CSL Limited, Teva Pharmaceutical Industries Ltd., Cadila Healthcare Ltd. and Johnson & Johnson International, Inc. The companies are focusing on extensive research and development activities to stay competitive in the market. Other competitive strategies include formation of alliances and partnerships.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=7331
Customers can also request for 10% free customization on this report.
“The Global Bleeding Disorders Drugs Market is anticipated to gain an exponential growth in the next five years, but market for sure will see some challenges. New investors or competitors can face issues like expensive hemophilia drugs and weak reimbursements by the health insurance companies. The rising cases of bleeding disorders will be the major driving factor for Global Bleeding Disorders Drugs Market. In the forecast period, Asia-Pacific region will be the fastest growing and dominating region in the Global Bleeding Disorders Drugs Market. The significant growth in this market could be due to the rising government initiatives into healthcare sector and advancements in the drugs market for bleeding disorders treatment.” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Global Bleeding Disorders Drugs Market By Drug Type (Plasma-derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antifibrinolytics, Fibrin Sealants, Others), By Disease Type (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Gender (Male v/s Female), By End User (Hospitals, Hemophilia Treatment Centers, Research Institutes, Others), By Region, Competition Forecast & Opportunities, 2026F”, has evaluated the future growth potential of Global Bleeding Disorders Drugs Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Bleeding Disorders Drugs Market.
Mr. Ken Mathews
708 Third Avenue,
New York – 10017